ARS Pharmaceuticals (SPRY) Insider Thompson Buys 30,000 Shares

Peter Thompson bought 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. The value of this transaction was not disclosed, but the stock closed at $8.54 on that day.

Inside Peter Thompson's Trade

Thompson's purchase is part of a trend among company insiders, as several have made similar acquisitions on the same date. Notably, Phillip Schneider, Pratik Shah, Saqib Islam, and Brent Saunders each acquired 30,000 shares on June 24, 2026. This coordinated buying may signal confidence in the company's future prospects.

Other Institutional Activity in ARS Pharmaceuticals

Several other institutional investors hold significant stakes in ARS Pharmaceuticals. For example, Rubric Capital Management LP added 540,804 shares, bringing its total to 8,540,861 shares valued at approximately $33.4 million. In contrast, RA Capital Management, L.P. holds 10,860,977 shares, valued at around $42.5 million, but did not make any changes to its position. Deerfield Management Company, L.P. and Orbimed Advisors LLC also maintained their holdings, reflecting stability among major investors.

ARS Pharmaceuticals, Inc. Stock Up 107.8%

As of the publishing date, ARS Pharmaceuticals' shares are trading at $8.54, up significantly from their 52-week low of $4.07. This rise reflects investor optimism after a low trading period, and the stock currently sits below its 52-week high of $13.15. The stock's recent performance could be impacted by the insider purchases and overall market conditions.

Recent Earnings

In its last earnings report, ARS Pharmaceuticals posted revenue of $116.9 million, showing a 14.2% growth compared to the previous year. However, the company reported an earnings per share (EPS) of -$2.18, indicating it is not currently profitable. The next earnings report is scheduled for November 10, 2026, and could provide further insights into the company's financial health.

Analysts Set New Price Targets

On June 25, 2026, Leerink Partners maintained an "Outperform" rating for ARS Pharmaceuticals with a price target of $24, slightly down from their previous target of $25. This came just before their August 13 update, where they set a new price target of $18 but also maintained the Outperform rating. Analysts generally hold a positive outlook, with a consensus price target of $22.5 based on four recommendations.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions, including an innovative needle-free intranasal delivery of epinephrine. Founded in 2015 and based in San Diego, California, the company aims to improve emergency treatment options for anaphylaxis and related conditions, which makes recent insider purchases particularly noteworthy as they signal confidence in the company’s growth potential.

Bottom Line

The insider trading activity at ARS Pharmaceuticals indicates a strong belief in the company's future by its leadership. With the next earnings report on November 10, 2026, investors will be keeping an eye on both financial performance and any additional insider movements. This 13F filing reflects past holdings and may not represent current positions, so further disclosures could be forthcoming.